InVivo Therapeutics enrolls 17th patient in INSPIRE study: 4 notes

InVivo Therapeutics enrolled another patient in its INSPIRE Study, testing the Neuro-Spinal Scaffold’s efficacy and safety for complete thoracic AIS A spinal cord injury.

Advertisement

Here are four notes:

 

1. James Harrop, MD, and Josh Heller, MD, of Philadelphia-based Thomas Jefferson University Hospital, implanted the device in the patient about 22 hours after injury.

 

2. Dr. Heller serves as the site’s principal investigator.

 

3. The INSPIRE Study now includes 17 enrolled patients in follow up.

 

4. Mark Perrin, InVivo’s CEO and chairman, said he is hopeful they will complete INSPIRE enrollment during the third quarter of 2017.

 

More articles on devices:
Conventus Orthopaedics names new CEO — 4 things to know
Mazor Robotics, Stryker, K2M & more: 19 device company key notes
Vertebral compression fracture devices market to reach $1.1M by 2022: 5 insights

 

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.